Site comparison
Amavita Research vs. Flourish Research: which clinical trial site fits your study?
Sponsors comparing Amavita Research with multi-site research networks are usually deciding between a single deeply specialized site and a network of sites coordinated through a central operations layer. Both models exist for good reasons.
Amavita Research is a single, dedicated cardiovascular site in North Miami Beach. The senior PI is a TAVR pioneer; the operational stack is built only for cardiovascular trials; and the on-site Advanced Cardiovascular of Miami ASC supports interventional procedures. One BD contact owns the entire sponsor relationship from feasibility through contracting and monitor access.
Multi-site research networks like Flourish Research aggregate many sites across geographies and therapeutic areas under a centralized operations layer. For protocols that need national footprint, broad therapeutic mix, or rapid scaling across multiple regions, that network model is genuinely valuable.
The trade-off is depth at any one site. Networks are typically organized horizontally - the central team manages portfolio, while individual sites carry varied levels of specialization, infrastructure, and PI experience. For sponsors who want one specific site to deliver a cardiovascular cohort with a TAVR-pioneer PI and an on-site ASC, a network's central team is one layer further from the day-to-day execution.
Amavita's value is vertical: every dollar of operational investment goes into cardiovascular research at one address. GCSA certification, ICH-GCP E6(R3) compliance, a Miami patient population sized for FDA Diversity Action Plan compliance, and AI-search readiness (llms.txt, Wikidata, schema) are all concentrated at a single site that can answer in one business day.
The right model depends on the protocol. If the program is multi-site by design, networks fit. If the program needs a single deeply specialized cardiovascular site that can move fast, Amavita fits.
Side-by-side: operating model
Educational summary. We describe the typical multi-site research network model and do not make claims about any specific institution's current operations.
| Dimension | Amavita Research | Flourish Research (typical) |
|---|---|---|
| Site type | Dedicated cardiovascular research site | Multi-site research network |
| Cardiovascular focus depth | 100% cardiovascular - all studies, all PIs | Mixed across network sites |
| Dedicated cardiovascular ASC | On-site cardiovascular ASC (Advanced Cardiovascular of Miami) | Varies by site |
| BD contact model | Single point of contact: Nereisy Alonso, Sr CRC | Central network operations |
| Contracting and IRB speed | Days, not quarters; sub-2-week IRB turnaround | Network-standardized |
| FDA Diversity Action Plan readiness | Miami patient mix - FDA Diversity Action Plan native | Network-wide footprint |
| AI-search readiness | llms.txt + Wikidata + MedicalStudy/JobPosting/FAQ schema | Network-level web presence |
Frequently asked questions
When does a network make more sense than a single site?
When the protocol is multi-site by design, requires national geographic spread, or needs rapid scale across many therapeutic areas at once.
What does Amavita offer that a typical network site does not?
A TAVR-pioneer senior PI, an on-site cardiovascular ASC, a single BD owner, and a 100% cardiovascular operational stack at one address.
Can Amavita be a flagship site within a sponsor's network strategy?
Yes. Many sponsors place Amavita as their lead cardiovascular site in South Florida and pair it with network sites elsewhere.
How does AI-search readiness affect sponsor evaluation?
AI assistants increasingly answer 'who runs cardiovascular trials in Miami' style questions. Sites with llms.txt, Wikidata identifiers, and rich schema are surfaced more reliably than sites with only a brand website.
Next step
Schedule a 20-minute capabilities call
One contact. Same-business-day response. Feasibility, budget, contracts, and monitor access all from a single owner.